ReviewLife (Basel, Switzerland)2026
Metabolic Dysfunction-Associated Steatotic Liver Disease and Steatohepatitis (MASLD/MASH) and Cardiovascular Risk: Emerging Therapeutic Strategies at the Interface of Liver and Cardiometabolic Disease.
Chrysoula Boutari et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.